Preliminary positive data on the BTK inhibitor, ibrutinib, in patients with anti-MAG antibody neuropathy and a specific mutational profile (MYD88L265P mutation, wild-type CXCR4 gene) need further confirmation on larger populations. The gene discussed is CXCR4; the disease is neuropathy.